foxo4-dri clinical trial nct eXoZymes (Nasdaq: EXOZ) is targeting metabolic dysfunction a layer deeper than appetite. In a recent Webull webinar, Chief Commercial Officer Damien Perriman walked investors through NCT, the company's first proof point. eXoZymes FOXO4-Dri 10mg - Polaris Peptides
Description
You could be spending good money on something that wont fix the problem
Parathyroid hormone, its fragments and their analogs for the treatment of osteoporosis
Mechanistic plausibility is largely theoretical pending human confirmation
Hoffman & Cook, 2006)
